Randomized Phase II trial of afatinib alone or with vinorelbine versus investigator`s choice of treatment in patients with HER2-positive breast cancer with progressive brain metastases after trastuzumab and/or labatinib-based therapy:LUX-Breast

  • J Cortes (Contributor)
  • V Dieras (Contributor)
  • J Ro (Contributor)
  • J Barriere (Contributor)
  • T Bachelot (Contributor)
  • S Hurvitz (Contributor)
  • E Le Rhun (Contributor)
  • S-B Kim (Contributor)
  • A Schneeweiss (Contributor)
  • JH Sohn (Contributor)
  • J-M Nabholtz (Contributor)
  • Kellokumpu-Lehtinen, P. (Contributor)
  • J Taguchi (Contributor)
  • F Piacentini (Contributor)
  • E Ciruelos (Contributor)
  • P Bono (Contributor)
  • M Ould-Kaaci (Contributor)
  • F Roux (Contributor)
  • H Joensuu (Contributor)

    Activity: Talk or presentationConference presentation


    Contributors: Cortes J, Dieras V, Ro J, Barriere J, Bachelot T, Hurvitz S, Le Rhun E, Kim S-B, Schneeweiss A, Sohn JH, Nabholtz J-M, Kellokumpu-Lehtinen P-L, Taguchi J, Piacentini F, Ciruelos E, Bono P, Ould-Kaaci M, Roux F, Joensuu H
    Period13 Dec 2014
    Event titleBreast cancer symposium 9-13.12.2014 Afatinib:1200
    Event typeOther
    Degree of RecognitionInternational